Integrated Intervention Improves Weight and Reduces Anemia in Term SGA InfantsIntegrated care package improves growth in small-for-gestational-age infants

This randomized clinical trial evaluated whether an integrated intervention package could improve growth and development in term small-for-gestational-age (SGA) infants living in low-resource neighborhoods of South Delhi, India. A total of 1300 term SGA infants were enrolled and randomized to receive either the integrated package or usual care through government programs. The intervention combined health, nutrition, early child stimulation, and psychosocial support. The comparator was usual care as provided by existing government services. The primary outcomes were weight and weight-for-age z score at 12 months. Follow-up extended to 12 months.

At 12 months, infants in the intervention group had a mean weight of 8.0 kg compared with 7.8 kg in the usual care group, a difference of 0.22 kg (95% CI, 0.11-0.32 kg). Weight-for-age z score was -1.3 in the intervention group versus -1.6 in usual care, an effect size of 0.24 (95% CI, 0.14-0.35). Both primary outcomes showed statistically significant improvements favoring the intervention.

Secondary outcomes also favored the intervention. Underweight prevalence was 23.9% in the intervention group versus 32.6% in usual care, a difference of -8.75 percentage points (95% CI, -13.70 to -3.80). Stunting prevalence was 20.1% versus 27.2%, a difference of -7.17 percentage points (95% CI, -11.85 to -2.49). Wasting prevalence was 13.9% versus 19.4%, a difference of -5.52 percentage points (95% CI, -9.63 to -1.41). Anemia prevalence was 34.0% in the intervention group compared with 72.5% in usual care, a striking difference of -38.49 percentage points (95% CI, -44.36 to -32.61). Neurodevelopmental scores also improved: cognitive scores had an effect size of 1.73 (95% CI, 0.32-3.14), language scores 2.74 (95% CI, 1.51-3.98), and motor composite scores 2.32 (95% CI, 1.25-3.38). Mortality was reported as 5 deaths in the intervention group versus 9 in usual care, but no statistical significance or confidence intervals were provided for this outcome, so it should be interpreted with caution.

Safety data were not reported. The JSON indicates that adverse events, serious adverse events, discontinuations, and tolerability were not reported. This limits the ability to assess the full risk-benefit profile of the intervention. The study did not report funding sources or conflicts of interest. No specific limitations were listed in the JSON, but the absence of safety reporting and the lack of statistical detail for mortality are notable gaps. The trial was conducted in a specific low-resource urban setting in India, which may affect generalizability to other populations.

These results add to the evidence that integrated, multi-domain interventions can improve growth and development in SGA infants. Prior landmark studies have often focused on single interventions, such as nutritional supplementation alone. This trial's package approach, combining health, nutrition, stimulation, and psychosocial support, yielded improvements across anthropometric, hematologic, and neurodevelopmental domains. The effect sizes are modest for weight but clinically meaningful for anemia and neurodevelopment. The anemia reduction is particularly large and may reflect multiple components, including nutrition and health care access.

For clinicians, these findings suggest that a comprehensive early intervention program for term SGA infants in low-resource settings can improve weight gain and reduce undernutrition and anemia at 12 months. However, the lack of safety data and the uncertain mortality effect warrant caution. The intervention's feasibility and scalability outside the trial setting are unknown. Questions remain about the durability of these benefits beyond 12 months, the specific active components, and whether similar results would be seen in other populations. The mortality signal, while not statistically tested, deserves further investigation in larger studies. Overall, the trial supports integrated care but does not provide sufficient evidence to change practice guidelines without additional safety and long-term data.